We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $156B
1-Year Est. Return 27.51%
This Fund
S&P 500
This Quarter Est. Return
+5.54%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.77%
AUM
$49.6B
AUM Growth
+$5.62B
Cap. Flow
+$2.56B
Cap. Flow %
5.15%
Top 10 Hldgs %
6.81%
Holding
1,885
New
111
Increased
738
Reduced
863
Closed
63

Top Sells

Rank Stock Value
1
INGR icon
Ingredion
INGR
+$85.6M
2
KEYS icon
Keysight
KEYS
+$83.3M
3
ATI icon
ATI
ATI
+$81.4M
4
KMT icon
Kennametal
KMT
+$66.6M
5
KDP icon
Keurig Dr Pepper
KDP
+$65.1M

Sector Composition

Rank Sector Weight
1 Financials 16.46%
2 Industrials 15.08%
3 Technology 14.03%
4 Consumer Discretionary 11.15%
5 Healthcare 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AKRO
1726
DELISTED
Akero Therapeutics
AKRO
$31K ﹤0.01%
+1,608
New +$30.5K
URGN icon
1727
UroGen Pharma
URGN
$1.88B
$31K ﹤0.01%
853
TVRD
1728
Tvardi Therapeutics
TVRD
$19M
$31K ﹤0.01%
40
DNR
1729
DELISTED
Denbury Resources, Inc.
DNR
$30K ﹤0.01%
24,459
-42,517
-63% -$77.2K
JOYY
1730
JOYY Inc
JOYY
$3.73B
$29K ﹤0.01%
409
-125,004
-100% -$9.54M
LSXMA
1731
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
$29K ﹤0.01%
1,077
-233,761
-100% -$6.47M
AXGN icon
1732
Axogen
AXGN
$2.46B
$27K ﹤0.01%
1,370
TUSK icon
1733
Mammoth Energy Services
TUSK
$130M
$26K ﹤0.01%
3,732
-7,301
-66% -$92.8K
ARQL
1734
DELISTED
Arqule Inc
ARQL
$26K ﹤0.01%
+2,402
New +$16.7K
NWS icon
1735
News Corp Class B
NWS
$17.2B
$25K ﹤0.01%
1,775
-39
-2% -$485
STML
1736
DELISTED
Stemline Therapeutics, Inc.
STML
$25K ﹤0.01%
1,609
CTO
1737
CTO Realty Growth
CTO
$827M
$24K ﹤0.01%
1,455
-4,218
-74% -$69K
RBBN icon
1738
Ribbon Communications
RBBN
$379M
$24K ﹤0.01%
4,975
TPC
1739
Tutor Perini Cor
TPC
$4.51B
$23K ﹤0.01%
1,665
MTZ icon
1740
MasTec
MTZ
$21B
$21K ﹤0.01%
410
-8
-2% -$395
STMP
1741
DELISTED
Stamps.com, Inc.
STMP
$21K ﹤0.01%
455
-786
-63% -$45K
BNGO icon
1742
Bionano Genomics
BNGO
$12.7M
$20K ﹤0.01%
14
CACI icon
1743
CACI
CACI
$11.3B
$19K ﹤0.01%
94
-115,657
-100% -$22.9M
BFX
1744
DELISTED
BowFlex Inc.
BFX
$19K ﹤0.01%
8,406
-14,607
-63% -$57.6K
TGTX icon
1745
TG Therapeutics
TGTX
$7.07B
$18K ﹤0.01%
2,119
PEGA icon
1746
Pegasystems
PEGA
$5.16B
$17K ﹤0.01%
+480
New +$17.1K
COLL icon
1747
Collegium Pharmaceutical
COLL
$1.15B
$16K ﹤0.01%
1,187
LCNB icon
1748
LCNB Corp
LCNB
$282M
$16K ﹤0.01%
818
-15
-2% -$257
DCPH
1749
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16K ﹤0.01%
708
OHI icon
1750
Omega Healthcare
OHI
$14.7B
$15K ﹤0.01%
+413
New +$15.1K

Similar funds

Victory Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Victory Capital Management held 1,885 positions worth $49.6B, up 13% from $44B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.

Victory Capital Management deployed $2.56B of net new capital in Q2 2019, opening 111 new positions and adding to 738 existing holdings. Its largest new stake was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.

By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Ingredion, an estimated $85.6M trimmed.

  • Victory Capital Management's largest Q2 2019 buy was Goldman Sachs ActiveBeta US Large Cap Equity ETF: 3,081,520 shares worth $181M.
  • Victory Capital Management added most to KLA in Q2 2019, an estimated $151M increase.
  • Victory Capital Management's biggest Q2 2019 reduction was Ingredion, cutting an estimated $85.6M.
  • Victory Capital Management fully exited Teladoc Health in Q2 2019, selling an estimated $50.5M.
  • Victory Capital Management's ten largest holdings make up 6.8% of its $49.6B portfolio in Q2 2019.
  • Victory Capital Management opened 111 new positions and closed 63 in Q2 2019.
  • Victory Capital Management's portfolio value rose 13% quarter-over-quarter to $49.6B.

Based on Victory Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.